Clinical trial
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or…
NCT00357708 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00357708 |
|---|---|
| Title | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases |
| Official title | A Phase I Trial of SAHA (NSC 701852) and Decitabine (IND 50733, NSC 127716) in Patients With Relapsed, Refractory or Poor Prognosis Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(15, 17)(q22, q12), Adult Acute Myeloid Leukemia With t(16, 16)(p13, Adult Acute Myeloid Leukemia With t(8 and 9 more |
| Intervention type | Drug, Other |
| Interventions | decitabine, vorinostat, laboratory biomarker analysis, pharmacological study |
| Enrollment | 50 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2009 |
| First posted | Jul 27, 2006 |
| Last update posted | Jan 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: